已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial

尼妥珠单抗 医学 生活质量(医疗保健) 头颈部癌 随机对照试验 内科学 顺铂 放射治疗 肿瘤科 临床试验 癌症 外科 化疗 表皮生长因子受体 护理部
作者
Nandini Menon,Vijay Patil,Vanita Noronha,Amit Joshi,Atanu Bhattacharjee,Balajirao J Satam,Vijayalakshmi Mathrudev,Sarbani Ghosh Laskar,Kumar Prabhash
出处
期刊:Oral Oncology [Elsevier BV]
卷期号:122: 105517-105517 被引量:15
标识
DOI:10.1016/j.oraloncology.2021.105517
摘要

The addition of Nimotuzumab to radical chemoradiation (CRT) improved outcomes in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing radical CRT in a phase 3 randomized trial. The current study focuses on the quality of life (QoL) of patients in this trial. In this phase III randomized trial, patients with newly diagnosed, nonmetastatic, stage III/IV LAHNSCC of the oral cavity, oropharynx, hypopharynx, or larynx were randomized to receive cisplatin 30 mg/m2 or cisplatin 30 mg/m2 with nimotuzumab once a week with curative radiotherapy. The primary end point of the trial was PFS. The aim of the current study was to compare the QoL between the two arms. QoL was assessed using the EORTC QLQ-C30 (v3.0) and HN-35 (v1.0). The linear mixed-effects model was used for longitudinal analysis of QoL. 536 patients were randomized in this trial (268 in each arm) and 423 patients were included for QoL analysis. There was a significant change in the global health status QoL scores over time (p = 0.0016) with no difference between the two arms (p = 0.396). On longitudinal analysis there was a significant difference in the QoL scores in most of the function & symptom scales over time, but there was no significant difference in these scores between the two arms. QoL scores for most symptom scales worsened during treatment and improved thereafter in both arms. The addition of nimotuzumab to cisplatin based chemoradiation in LAHNSCC improved PFS, LRC and DFS without negatively impacting QoL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
6秒前
7秒前
淡然绝山发布了新的文献求助10
8秒前
8秒前
峰feng完成签到 ,获得积分10
9秒前
10秒前
不摇碧莲完成签到 ,获得积分10
12秒前
希希完成签到 ,获得积分10
15秒前
Zbre完成签到,获得积分10
16秒前
桐桐应助人间打气筒采纳,获得10
25秒前
27秒前
搜集达人应助科研通管家采纳,获得10
29秒前
大模型应助科研通管家采纳,获得20
29秒前
科研通AI2S应助科研通管家采纳,获得10
29秒前
29秒前
上官若男应助科研通管家采纳,获得30
29秒前
monster0101完成签到 ,获得积分10
33秒前
33秒前
酷炫的一笑完成签到,获得积分10
34秒前
完美世界应助GL采纳,获得10
40秒前
41秒前
鸭梨发布了新的文献求助10
41秒前
46秒前
咪呀完成签到,获得积分10
47秒前
etheral发布了新的文献求助10
48秒前
风趣小蜜蜂完成签到 ,获得积分10
48秒前
49秒前
优雅愚志完成签到,获得积分10
49秒前
51秒前
木木应助GL采纳,获得10
51秒前
song发布了新的文献求助10
52秒前
55秒前
负责怀莲发布了新的文献求助10
57秒前
Grandir发布了新的文献求助20
58秒前
1分钟前
kami完成签到 ,获得积分10
1分钟前
赵欣媛完成签到 ,获得积分10
1分钟前
科研通AI5应助Arui采纳,获得10
1分钟前
朴实的热狗完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989949
求助须知:如何正确求助?哪些是违规求助? 3532017
关于积分的说明 11255865
捐赠科研通 3270829
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882233
科研通“疑难数据库(出版商)”最低求助积分说明 809216